Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ixazomib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    47 result(s) found for: Ixazomib. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-003258-25 Sponsor Protocol Number: X16120 Start Date*: 2019-07-04
    Sponsor Name:Odense University Hospital
    Full Title: Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001681-28 Sponsor Protocol Number: C16027 Start Date*: 2016-10-27
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies.
    Medical condition: The patient population will consist of patients who have previously received and tolerated ixazomib in a Millennium-sponsored clinical study, and in the investigator’s opinion and confirmed by the ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004742-28 Sponsor Protocol Number: C16029 Start Date*: 2017-10-26
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda
    Full Title: A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Medical condition: Relapsed and/or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) NL (Completed) BE (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002503-26 Sponsor Protocol Number: X16082 Start Date*: 2017-03-14
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease
    Medical condition: Adult patiens after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004870 10018653 Graft-versus-host disease LLT
    19.1 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002749-23 Sponsor Protocol Number: AGMT_MM-1/EMN-13 Start Date*: 2015-01-19
    Sponsor Name:AGMT gGmbH
    Full Title: Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma
    Medical condition: refractory and/or relapsed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001394-13 Sponsor Protocol Number: C16021 Start Date*: 2015-08-12
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell...
    Medical condition: Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) DK (Completed) ES (Completed) SE (Completed) HU (Completed) FR (Completed) HR (Prematurely Ended) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003977-32 Sponsor Protocol Number: C16047 Start Date*: 2018-08-01
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Medical condition: Relapsed and/or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GR (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001757-16 Sponsor Protocol Number: DSMMXV Start Date*: 2016-11-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma
    Medical condition: Relapsed/refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002076-41 Sponsor Protocol Number: C16019 Start Date*: 2014-06-17
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant
    Medical condition: Newly diagnosed multiple myeloma (NDMM) following induction therapy and autologous stem cell transplant (ASCT)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) SE (Completed) DK (Completed) IT (Completed) PT (Completed) ES (Completed) AT (Completed) HU (Completed) DE (Completed) NL (Completed) GR (Completed) PL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-002711-94 Sponsor Protocol Number: HO124WM Start Date*: 2014-09-19
    Sponsor Name:HOVON Foundation
    Full Title: HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10054697 Waldenstrom's macroglobulinemia recurrent LLT
    21.1 100000004864 10054698 Waldenstrom's macroglobulinemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003266-14 Sponsor Protocol Number: HOVON126 Start Date*: 2014-11-06
    Sponsor Name:HOVON Foundation
    Full Title: Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologo...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) SE (Ongoing) NO (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004863-35 Sponsor Protocol Number: FMG-MM03/NMSG#23/15 Start Date*: 2016-08-01
    Sponsor Name:Hospital District of Helsinki and Uusimaa/Helsinki University Hospital HUS
    Full Title: A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients
    Medical condition: Multiple myeloma newly diagnosed transplant-eligible patients
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003907-20 Sponsor Protocol Number: C16051 Start Date*: 2019-07-10
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit
    Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002600-90 Sponsor Protocol Number: HO143 Start Date*: 2017-06-19
    Sponsor Name:HOVON Foundation
    Full Title: Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and ...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001947-28 Sponsor Protocol Number: T2017-002 Start Date*: 2019-06-11
    Sponsor Name:Therapeutic Advances in Childhood Leukemia Consortium (TACL)
    Full Title: A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
    Medical condition: Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LLy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001421-13 Sponsor Protocol Number: AGMT_MBC-10(X16087) Start Date*: 2016-08-31
    Sponsor Name:AGMT gGmbH
    Full Title: Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)
    Medical condition: Advanced (locally advanced inoperable or metastatic) triple negative breast cancer progressing after first-line therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002302-32 Sponsor Protocol Number: C16017 Start Date*: 2013-11-12
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029478 Nodular lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003590-10 Sponsor Protocol Number: HM19/123658 Start Date*: 2019-10-30
    Sponsor Name:University of Leeds
    Full Title: Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lena...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    20.0 100000004864 10028566 Myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004511-36 Sponsor Protocol Number: HM13/10993 Start Date*: 2015-09-28
    Sponsor Name:University Of Leeds
    Full Title: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with tha...
    Medical condition: Relasped and Refractory Mulitple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002089-37 Sponsor Protocol Number: EMN18 Start Date*: 2019-03-04
    Sponsor Name:EUROPEAN MYELOMA NETWORK
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAME...
    Medical condition: YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 02 02:54:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA